β-Lactam Antibiotics Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

β-Lactam Antibiotics DMPK and Bioanalytical Services

Quantifying β-lactam antibiotics is rarely a routine LC-MS/MS exercise. The same structural feature that defines this class—the β-lactam ring—also creates one of its biggest analytical liabilities: ex vivo degradation. Without controlled sample handling, stabilization strategy, and matrix-specific method design, parent-drug concentrations can shift before the sample ever reaches the instrument.

For β-lactam DMPK studies, the analytical challenge often goes beyond detecting the parent compound. Researchers may need to protect unstable analytes during collection and processing, capture low trough concentrations for Time > MIC-linked exposure analysis, manage extreme plasma-to-urine concentration differences, and separate true parent-drug signal from hydrolysis or degradation products.

Browse β-Lactam Drug Index Request Custom β-Lactam Method Support

Ring instabilityControl ex vivo hydrolysis before parent-drug concentration is compromised.

Plasma-to-urine shiftsHandle low plasma levels and high urine concentrations within study-specific workflows.

Product-level claritySeparate intact parent drug from hydrolysis, degradation, or transformation signals.

β-Lactam Workflow Risks DMPK Strategy Map

⚠

Fragile β-lactam ringHydrolysis and degradation can begin before injection.

🧪

Matrix-dependent behaviorPlasma, urine, tissue, and processed samples may require different controls.

📉

Low-trough measurementLLOQ and selectivity affect Time > MIC-oriented interpretation.

🧬

Hydrolysis product trackingMetID helps explain parent-drug loss and related signals.

Stability-locked workflow design.Creative Proteomics connects parent-drug quantification, plasma/urine exposure, pre-analytical stabilization, hydrolysis product profiling, MetID, β-lactamase inhibitor panel development, and custom DMPK workflows in one study-aware strategy.

β-Lactam Drug Index

Find the β-Lactam Compound Behind the Study

Whether troubleshooting a failed assay or navigating a challenging matrix, simply search by compound name, scan the A–Z index, or combine cross-referenced field tags to locate the exact DMPK clearance and quantification protocols you need.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only β-lactams matching all selected values.

17 entries · Page 1 of 3

Analytical Pain Points

What Drives Assay Failure in β-Lactam Studies?

Selecting the compound is only the first step. β-lactam DMPK studies frequently fail because the method is treated like a generic parent-drug assay. The real risks appear earlier: sample instability, ring hydrolysis, matrix-driven ion suppression, trough-level sensitivity gaps, urine overload, and co-administered inhibitor complexity.

Ex Vivo Hydrolysis: The Silent PK Data Killer

The β-lactam ring is the defining structural feature of this class—and one of its main analytical liabilities. Depending on structure, matrix, pH, temperature, and handling time, β-lactams can degrade before analysis.

Our responseStability-controlled workflows with defined collection conditions, pH control, temperature management, processed sample stability, freeze–thaw testing, and degradation product tracking where required.

Stability & Degradation →

Trough-Level Quantification and the Time > MIC Window

The tail of the concentration-time curve can be as important as the peak. If the method cannot measure low concentrations near the trough range, exposure-pattern interpretation may be compromised.

Our responseLLOQ, MRM transitions, chromatographic retention, matrix effect control, and signal-to-noise optimization for low-level β-lactam quantification.

LC-MS/MS Quantification →

Plasma-to-Urine Dynamic Range

Plasma may demand high sensitivity; urine may require aggressive dilution, carryover control, and saturation prevention. Treating them as interchangeable matrices is a common route to unusable data.

Our responseMatrix-specific calibration, dilution integrity, carryover mitigation, and sample preparation workflows for both low- and high-concentration sample sets.

Plasma & Serum Bioanalysis →

β-Lactamase Inhibitor Co-Analysis

Companion inhibitors can have different polarity, pKa, retention, ionization efficiency, and concentration ranges from the parent antibiotic. A single-analyte assay cannot simply be stretched into a panel.

Our responseCustomized multi-analyte LC-MS/MS methods using analyte-specific extraction, chromatographic separation, MRM optimization, and matrix-matched calibration.

Multi-Analyte Panels →

Hydrolysis and Transformation Product Tracking

A drop in parent-drug signal does not automatically mean clearance. It may reflect ex vivo degradation, hydrolysis, matrix instability, or transformation products.

Our responseTargeted MetID or HRMS-supported profiling to identify hydrolysis-related products, degradation products, and suspected transformation products.

MetID →

Focused Service Paths

Four Practical Routes for β-Lactam Studies

Instead of pushing every DMPK service into one project, these paths help researchers choose the analytical direction that fits the compound, matrix, concentration range, and research objective.

High-Sensitivity Parent Drug PK Profiling

For studies that require parent β-lactam concentration data across plasma, serum, urine, tissue, or other biological matrices.

Parent-drug PK sample analysis
Plasma or serum exposure profiling
Low trough-level quantification
Time-course concentration measurement

LC-MS/MS Drug Quantification →

Pre-Analytical Stabilization and Degradation Control

For studies where β-lactam ring cleavage, processing delay, or storage conditions may compromise parent-drug integrity.

Labile β-lactams
Bench-top stability concerns
Autosampler stability
Freeze-thaw evaluation

Stability & Forced Degradation →

Transformation and Hydrolysis Product Identification

For studies where parent-drug disappearance must be explained rather than simply reported.

Hydrolysis product confirmation
Degradation-related signal investigation
Phase I / phase II product evaluation
Parent-only assay troubleshooting

Metabolite Identification →

Multiplexed β-Lactam and Inhibitor Panels

For studies involving multiple β-lactams, β-lactamase inhibitor combinations, comparative exposure analysis, or broader anti-infective coverage.

Multi-β-lactam quantification
β-lactam / inhibitor combinations
Comparative antibiotic exposure
Custom anti-infective analyte panels

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted β-Lactam?

If you are developing a novel β-lactam scaffold, a proprietary β-lactamase inhibitor, a salt or hydrate form, a hydrolysis product, a degradation product, or a complex biological matrix, an off-the-shelf assay may not be enough.

Creative Proteomics develops de novo LC-MS/MS and DMPK workflows for challenging anti-infective analytes. Share your target structure, matrix, expected LLOQ, stabilization concerns, and readout requirements to initiate a feasibility review.

Target structure and analyte behavior

Matrix and expected concentration range

Required LLOQ and sensitivity window

Stabilization and sample handling concerns

MetID or degradation profiling needs

Single-analyte assay or panel workflow